4-amino-1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one | 107036-47-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 4-amino-1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
• 英文别名: 4-amino-1-[(2R,4S,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-1,3,5-triazin-2-one
• CAS: 107036-47-5
• 化学式: C₂₉H₃₀N₄O₆
• 分子量: 530.58
• InChiKey: TZTBQTMMEYFQKL-JIMJEQGWSA-N

物化性质

• 沸点：
  708.1±70.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.89
• 重原子数：
  39.0
• 可旋转键数：
  9.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  130.95
• 氢给体数：
  2.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  N,N-二甲基甲酰胺二甲基缩醛 、 4-amino-1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one 以 N,N-二甲基甲酰胺 为溶剂， 以86.3%的产率得到
  参考文献：
  名称：

  一种脱氧胞苷类有机合成中间体及其制备方法

  摘要：

  本发明公开了一种脱氧胞苷类有机合成中间体及其制备方法。本发明以5‑氮杂‑2'‑脱氧胞苷为原料，经过4位氨基保护、5'位羟基保护后得到目的产物。这两种保护方法可以变换顺序，均可得到目标产物。该合成方法操作简单、条件温和、产率高重复性好。本发明所提供的制备方法工艺简单，成本较低，反应条件温和容易控制，生产过程安全可靠，适合工业化。

  公开号：

  CN109232692A
• 作为产物：
  描述：

  5'-O-(4,4'-dimethoxytrityl)-5-azacytidine 在 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile 、 三正丁基氢锡 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 2.0h， 生成 4-amino-1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
  参考文献：
  名称：

  Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogs

  摘要：

  5-Substituted 2',3'-dideoxycytidine analogues have been synthesized and evaluated in vitro for their capabilities to protect T4+ lymphocytes from the cytopathic effects of the HTLV-III/LAV (HIV) virus, the causative agent of acquired immunodeficiency syndrome (AIDS). These analogues were designed to be more lipophilic than 2',3'-dideoxycytidine (ddC) in order to enhance central nervous system penetration. Earlier reports had shown that ddC is a potent protective agent. When ddC is substituted at the 5-position with either methyl or bromo substituents, activity is completely abolished. However, when the substitution is fluoro (5-F-ddC), both activity and potency are retained. 2',3'-Dideoxy-5-azacytidine is also protective but more toxic than ddC or 5-F-ddC. In a different approach, an attempt was made to utilize ddCMP, ddTMP, and ddAMP as preformed nucleotides in order to circumvent the generally low level of phosphorylation achieved with dideoxynucleosides which function as relatively poor substrates for the cellular kinases. Only ddAMP is as active as its nucleoside precursor. Because ddAMP is not more active than ddA at low concentrations, it is possible that the active agent is ddA which is generated from ddAMP prior to cell entry.

  DOI：

  10.1021/jm00388a020

文献信息

• Synthesis and Properties of Oligonucleotides Containing 5-Aza-2′-deoxycytidine
  作者：Ramon Eritja、Victor E. Marquez、Ramon Güimil García

  DOI：10.1080/07328319708006144

  日期：1997.7

  The preparation of a protected derivative of 5-aza-2'-deoxycytidine carrying the 2-(p-nitrophenyl)ethyl group is described. The new derivative is useful for the preparation of oligonucleotides containing 5-aza-2'-deoxycytidine using a special methodology that avoids the use of ammonia.
• DRISCOLL, JOHN S.;MARQUEZ, VICTOR E.;KIM, CHONG-HO;KELLEY, JAMES A.
  作者：DRISCOLL, JOHN S.、MARQUEZ, VICTOR E.、KIM, CHONG-HO、KELLEY, JAMES A.

  DOI：——

  日期：——
• GODDARD, AMANDA J.;MARQUEZ, VICTOR E., NUCLEOSIDES AND NUCLEOTIDES, 8,(1989) N-6, C. 1015-1018
  作者：GODDARD, AMANDA J.、MARQUEZ, VICTOR E.

  DOI：——

  日期：——
• [EN] COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF<br/>[FR] COMPOSITIONS POUR L'ÉDITION DE TRANSCRITS MECP2 ET PROCÉDÉS ASSOCIÉS
  申请人：[en]WAVE LIFE SCIENCES LTD.

  公开号：WO2023049477A2

  公开（公告）日：2023-03-30

  Among other things, the present disclosure provides oligonucleotides, compositions and methods thereof that can bring about specific editing of a target adenosine in a target RNA molecule. Such oligonucleotides, compositions and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders, diseases and syndromes that can benefit from adenosine modification.